Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 980 versus trastuzumab in HER2-positive early breast cancer
RBR-37f338Phase 3Recruiting
- Sponsor
- Hospital de Caridade de Ijuí
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of abp 980, trastuzumab in breast cancer, sponsored by Hospital de Caridade de Ijuí. Started May 2013; status: recruiting.
02
Drugs
abp 980trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on RBR-37f338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-37f338.